Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 5/20 | 0.48 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16390022 | 0.98 | DNM1 (0.46) | DNM1SPHK1CA12CA1CA2 | |
| SCHEMBL486756 | 0.98 | DNM1 (0.46) | DNM1SPHK1CA12CA1CA2 | |
| SCHEMBL15703305 | 0.98 | DNM1 (0.46) | DNM1SPHK1CA12CA1CA2 | |
| SCHEMBL2041621 | 0.98 | DNM1 (0.46) | DNM1SPHK1CA12CA1CA2 | |
| SCHEMBL16390519 | 0.98 | DNM1 (0.46) | DNM1SPHK1CA12CA1CA2 | |
| SCHEMBL2037635 | 0.98 | DNM1 (0.46) | DNM1SPHK1CA12CA1CA2 | |
| SCHEMBL2042635 | 0.98 | DNM1 (0.46) | DNM1SPHK1CA12CA1CA2 | |
| SCHEMBL123831 | 0.98 | DNM1 (0.46) | DNM1SPHK1CA12CA1CA2 | |
| SCHEMBL2041646 | 0.98 | DNM1 (0.46) | DNM1SPHK1CA12CA1CA2 | |
| SCHEMBL16389920 | 0.98 | DNM1 (0.46) | DNM1SPHK1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 253 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6503945-B2 | Nontoxic, drug delivery, gene therapy; therapy of cystic fibrosis | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2003-01-07 | — | — | US | claimed |
| US-20020077366-A1 | Novel cationic amphiphiles containing N-hydroxyalkyl group for intracellular delivery of biologically active molecules | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH | 2002-06-20 | — | — | US | claimed |
| US-6346516-B1 | DRUG DELIVERY OF (QUATERNARY) AMINE SALT AND MACROMOLECULE; GENE THERAPY | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2002-02-12 | — | — | US | claimed |
| US-12497437-B2 | Modified Mullerian Inhibiting Substance (MIS) proteins and uses thereof for the treatment of diseases | THE GENERAL HOSPITAL CORPORATION | 2025-12-16 | — | — | US | disclosed |
| US-20250346632-A1 | SERPIN PEPTIDES AND METHODS OF USING THE SAME | SERPIN PHARMA LLC (US) | 2025-11-13 | — | — | US | disclosed |
| US-12398179-B2 | Nanomolar peptides and derivatives to differentially modulate ephrin receptors | Sanford Burnham Prebys Medical Discovery Institute (US) | 2025-08-26 | — | — | US | disclosed |
| US-20250228922-A1 | METHODS FOR TREATMENT OF DISEASES | SERPIN PHARMA, LLC | 2025-07-17 | — | — | US | disclosed |
| US-12357675-B2 | Efficient protein expression in vivo using modified RNA (mod-RNA) | THE GENERAL HOSPITAL CORPORATION | 2025-07-15 | — | — | US | disclosed |
| WO-2025105506-A1 | NUCLEIC ACID, DRUG COMPOSITION, AND METHOD OF PRODUCING NUCLEIC ACID | アンジェス株式会社 | 2025-05-22 | — | — | WO | disclosed |
| US-12291581-B2 | Serpin peptides and methods of using the same | SERPIN PHARMA, LLC (US) | 2025-05-06 | — | — | US | disclosed |
| US-20240277812-A1 | USE OF MULLERIAN INHIBITING SUBSTANCE (MIS) PROTEINS FOR CONTRACEPTION AND OVARIAN RESERVE PRESERVATION | THE GENERAL HOSPITAL CORPORATION (US) | 2024-08-22 | — | — | US | disclosed |
| US-20020062044-A1 | Process for synthesis of novel cationic amphiphiles containing N-hydroxyalkyl group for intracellular delivery of biologically active molecules | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH | 2002-05-23 | — | — | US | disclosed |
| EP-1190086-A2 | GENETIC MODIFICATION OF MALE GERM CELLS FOR GENERATION OF TRANSGENIC SPECIES AND GENETIC THERAPIES | Cedars-Sinai Medical Center (US) | 2002-03-27 | — | — | EP | disclosed |
| US-6346516-B1 | DRUG DELIVERY OF (QUATERNARY) AMINE SALT AND MACROMOLECULE; GENE THERAPY | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2002-02-12 | — | — | US | disclosed |
| US-6333433-B1 | COUPLING ALIPHATIC ALDEHYDE WITH ALKYLAMINE, REDUCING IMINE TO SECONDARY AMINE, REACTING WITH PROTECTED HYDROXYALKYL HALIDE, DEPROTECTING, QUATERNIZING N-HYDROXYALKYL GROUP CONTAINING TERTIARY AMINE WITH ALKYL HALIDE OR TOSYLATE IN POLAR SOLVENT | COUNCIL OF SCIENTIFIC INDUSTRIAL RESEARCH (IN) | 2001-12-25 | — | — | US | disclosed |
| WO-2001087934-A2 | TREATMENT OF NEOPLASIA/TRANSFORMATION USING A PITUITARY TUMOR TRANSFORMING GENE CARBOXY TERMINAL PEPTIDES | CEDARS-SINAI MEDICAL CENTER (US) | 2001-11-22 | — | — | WO | disclosed |
| WO-2001088116-A2 | METHOD OF MODULATING ACTIVATION OF LYMPHOCYTES VIA MODULATION OF PITUITARY TUMOR TRANSFORMING GENE, RELATED SCREEINING METHODS | CEDARS-SINAI MEDICAL CENTER (US) | 2001-11-22 | — | — | WO | disclosed |
| WO-2001087935-A2 | METHODS OF MODULATING ANGIOGENESIS BY REGULATING THE EXPRESSION OF PITUITARY TUMOR TRANSFORMING GENE (PTTG) | CEDARS-SINAI MEDICAL CENTER (US) | 2001-11-22 | — | — | WO | disclosed |
| WO-2001087039-A2 | TREATMENT OF NEOPLASIA / TRANSFORMATION USING PITUITARY TUMOR TRANSFORMING GENE 2 | CEDARS-SINAI MEDICAL CENTER (US) | 2001-11-22 | — | — | WO | disclosed |
| WO-2000069257-A2 | GENETIC MODIFICATION OF MALE GERM CELLS FOR GENERATION OF TRANSGENIC SPECIES AND GENETIC THERAPIES | CEDARS-SINAI MEDICAL CENTER (US) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077366-A1 | Novel cationic amphiphiles containing N-hydroxyalkyl group for intracellular delivery of biologically active molecules | NPC1L1, ABCB4, ANXA1 | DNM1 188/4885SPHK1 753/4885CA12 3351/4885 |
| US-20020062044-A1 | Process for synthesis of novel cationic amphiphiles containing N-hydroxyalkyl group for intracellular delivery of biologically active molecules | CHMP4B, SLC43A1, SCAMP3 | DNM1 265/4885SPHK1 487/4885CA12 1845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.